NMRA Stock Analysis: Buy, Sell, or Hold?
NMRA - Neumora Therapeutics, Inc. Common Stock
$1.95
0.02 (1.04%)
▲
5d:
-21.05%
30d:
-39.06%
90d:
+9.55%
WAIT
LOW Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: Mar 30, 2026
0d
Smart Money Distribution
NMRA is up 7.2% this week, but smart money is buying puts. Top strike: $2.5 2026-04-17 with 436 OI. Put ratio: 100% View Scanner →
Strength: 8.6/10
Get Alerted When NMRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NMRA is down 21.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NMRA is down 21.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NMRA is currently trading at $1.95, which is considered oversold relative to its 30-day fair value range of $2.46 to $3.37.
Technical Outlook: Technically, NMRA is in a uptrend. Immediate support is located at $1.82, while resistance sits at $2.82.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.91 (+356.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NMRA is in a uptrend. Immediate support is located at $1.82, while resistance sits at $2.82.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.91 (+356.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.46 -
$3.37
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 356.8% below Wall St target ($8.91)
- WARNING: Recommendation downgraded due to -21.1% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$2.46 -
$3.37
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.82
Resistance Level
$2.82
Current Trend
Uptrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.85
Wall Street Target
$8.91
(+356.8%)
Share & Embed Analysis
Last updated: March 31, 2026 6:41 PM ET
Data refreshes hourly during market hours. Next update: 7:41 PM
Data refreshes hourly during market hours. Next update: 7:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NMRA showing a specific setup today?
Insider Activity (6 Months)
2
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Daljit Singh Aurora
SELL
6165 shares
2026-02-17
Joshua Pinto
SELL
5967 shares
2026-02-17
Michael Lee Milligan
SELL
1436 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 66 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 59 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 49 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 60 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 47 HOLD |